- Home
- IMNN vs PHIO Comparison
IMNN vs PHIO Comparison
Compare IMNN & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- PHIO
- Stock Information
- Founded
- IMNN 1982
- PHIO 2011
- Country
- IMNN United States
- PHIO United States
- Employees
- IMNN N/A
- PHIO N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- PHIO Health Care
- Exchange
- IMNN Nasdaq
- PHIO Nasdaq
- Market Cap
- IMNN 12.1M
- PHIO 11.9M
- IPO Year
- IMNN 1985
- PHIO N/A
- Fundamental
- Price
- IMNN $7.61
- PHIO $2.43
- Analyst Decision
- IMNN Buy
- PHIO Strong Buy
- Analyst Count
- IMNN 2
- PHIO 2
- Target Price
- IMNN $210.00
- PHIO $9.00
- AVG Volume (30 Days)
- IMNN 405.2K
- PHIO 2.7M
- Earning Date
- IMNN 08-05-2025
- PHIO 08-13-2025
- Dividend Yield
- IMNN N/A
- PHIO N/A
- EPS Growth
- IMNN N/A
- PHIO N/A
- EPS
- IMNN N/A
- PHIO N/A
- Revenue
- IMNN N/A
- PHIO N/A
- Revenue This Year
- IMNN N/A
- PHIO N/A
- Revenue Next Year
- IMNN N/A
- PHIO N/A
- P/E Ratio
- IMNN N/A
- PHIO N/A
- Revenue Growth
- IMNN N/A
- PHIO N/A
- 52 Week Low
- IMNN $5.55
- PHIO $0.97
- 52 Week High
- IMNN $54.75
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- IMNN 38.74
- PHIO 50.01
- Support Level
- IMNN $6.51
- PHIO $2.40
- Resistance Level
- IMNN $8.10
- PHIO $2.70
- Average True Range (ATR)
- IMNN 1.32
- PHIO 0.20
- MACD
- IMNN 0.20
- PHIO -0.00
- Stochastic Oscillator
- IMNN 20.04
- PHIO 10.26
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.